Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
6 undervalued US shares that crushed earnings
Atlassian and CarMax remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued REIT offers attractive yield post earnings
Resilient income, attractive yield for Aussie REIT.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 5.60 | 0.06% |
| CAC 40 | 8,539.31 | 40.29 | -0.47% |
| DAX 40 | 26,252.97 | 85.64 | -0.33% |
| Dow JONES (US) | 53,459.78 | 272.63 | -0.51% |
| FTSE 100 | 10,722.46 | 2.16 | 0.02% |
| HKSE | 25,471.15 | 17.92 | 0.07% |
| NASDAQ | 26,644.91 | 84.25 | -0.32% |
| Nikkei 225 | 67,460.73 | 1,759.52 | -2.54% |
| NZX 50 Index | 13,866.18 | 144.20 | 1.05% |
| S&P 500 | 7,745.06 | 40.70 | -0.52% |
| S&P/ASX 200 | 9,070.00 | 5.20 | 0.06% |
| SSE Composite Index | 3,990.30 | 7.65 | 0.19% |